Reimbursement &
Health Policy Support


Your one-stop resource for coding,
reimbursement support, and education.

 

Bracco Reimbursement Hotline: 1-800-349-1388
askbracco@reimbursement.bracco.com

Reimbursement & Health Policy Support

Your one-stop resource for coding, reimbursement support, and education.

Bracco Reimbursement Hotline:
1-800-349-1388
askbracco@reimbursement.bracco.com

Resources

Click below to download the Bracco HCPCS Code Book

Click on a product below to learn more about its reimbursement.

Please see Full Prescribing Information including Boxed WARNINGS and Medication Guide for MultiHance®.

To view our HCPCS code book, please click here.

For more information on MultiHance, please visit braccomr.com.

Please see Full Prescribing Information including Boxed WARNINGS and Medication Guide for ProHance®.

To view our HCPCS code book, please click here.

For more information on ProHance, please visit braccomr.com.

Please see Full Prescribing Information including Boxed WARNINGS for LUMASON®.

To view our HCPCS code book, please click here.

To access hospital outpatient reimbursement for LUMASON, please click here. To access physician’s office reimbursement for LUMASON, please click here. 

For more information on LUMASON, please visit lumason.com.

Please see Full Prescribing Information for VARIBAR® HONEYVARIBAR® THIN HONEY, VARIBAR® PUDDING, VARIBAR® NECTAR, and VARIBAR® THIN LIQUID.

To view our HCPCS code book, please click here.

To access our comprehensive reimbursement for VARIBAR, please click here.

For more information on VARIBAR, please visit varibarmbs.com.

Please see Full Prescribing Information including Boxed WARNINGS for CARDIOGEN‑82®.

To view our HCPCS code book, please click here.

To access our comprehensive reimbursement for CARDIOGEN‑82, please click here.

For more information on CARDIOGEN‑82, please visit cardiogen.com.

Connect With Your Local Bracco Rep

Webinars

Access CE-accredited, value-based webcasts about coding, coverage, and payment.

2022 Cardiac PET Coding and Reimbursement

Presented by
Denise A. Merlino, CPC, MBA, CNMT

Sign up to receive educational mailings and invitations to future webinars

All Fields Mandatory


Certification

By checking this box and clicking the register button of this page, I certify that I am a U.S. healthcare professional, and give permission for Bracco Diagnostics Inc., or parties acting on its behalf, to contact me with information regarding Bracco Diagnostics Inc. products and solutions, invitations to events and seminars, industry updates and other notifications. I understand that the information I provide will not be given to anyone outside Bracco Diagnostics Inc. except for the agents or representatives processing this request.



ProHance® (Gadoteridol) Injection, 279.3 mg/mL
and
ProHance® MultipackTM (Gadoteridol) Injection, 279.3 mg/mL

Indications and Usage:

CENTRAL NERVOUS SYSTEM
ProHance® (Gadoteridol) Injection, 279.3 mg/mL is indicated for use in MRI in adults and pediatric patients including term neonates to visualize lesions with disrupted blood brain barrier and/or abnormal vascularity in the brain (intracranial lesions), spine and associated tissues.

EXTRACRANIAL/EXTRASPINAL HEAD AND NECK
ProHance (Gadoteridol) Injection, 279.3 mg/mL is indicated for use in MRI in adults to visualize lesions in the head and neck.

IMPORTANT SAFETY INFORMATION:

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS

Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs.

  • The risk for NSF appears highest among patients with:
    • chronic, severe kidney disease (GFR <30 mL/min/1.73m2), or
    • acute kidney injury.
  • Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
  • For patients at highest risk for NSF, do not exceed the recommended ProHance dose and allow a sufficient period of time for elimination of the drug from the body prior to re-administration.

 

CONTRAINDICATIONS
Contraindicated in patients with known allergic or hypersensitivity reactions to ProHance.

WARNINGS AND PRECAUTIONS
Nephrogenic Systemic Fibrosis: NSF has occurred in patients with impaired elimination of GBCAs. Higher than recommended dosing or repeated dosing appears to increase risk.
Hypersensitivity Reactions: Anaphylactic and anaphylactoid reactions have been reported, involving cardiovascular, respiratory, and/or cutaneous manifestations. Some patients experienced circulatory collapse and died. In most cases, initial symptoms occurred within minutes of administration and resolved with prompt emergency treatment. Prior to ProHance administration, ensure the availability of trained personnel and medications to treat hypersensitivity reactions. Consider these risks, especially in patients with a history of hypersensitivity reactions or a history of asthma or other allergic disorders.
Gadolinium Retention: Gadolinium is retained for months or years in several organs. The highest concentrations have been identified in the bone, followed by brain, skin, kidney, liver, and spleen. Linear GBCAs cause more retention than macrocyclic GBCAs. Consequences of gadolinium retention in the brain have not been established, but they have been established in the skin and other organs in patients with impaired renal function.
Acute Kidney Injury: In patients with chronically reduced renal function, acute kidney injury requiring dialysis has occurred with the use of GBCAs. The risk of acute kidney injury may increase with increasing dose of the contrast agent; administer the lowest dose necessary for adequate imaging.

ADVERSE REACTIONS
The most commonly reported adverse reactions are nausea and taste perversion with an incidence ≥ 0.9%.

USE IN SPECIFIC POPULATIONS
Pregnancy: GBCAs cross the human placenta and result in fetal exposure and gadolinium retention. Use only if imaging is essential during pregnancy and cannot be delayed.
Lactation: There are no data on the presence in human milk, the effects on the breastfed infant, or the effects on milk production. However, published lactation data on other GBCAs indicate that 0.01 to 0.04% of the maternal gadolinium dose is present in breast milk.
Pediatric Use: The safety and effectiveness of ProHance have been established for use with MRI to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine, and associated tissues in pediatric patients from birth, including term neonates, to 17 years of age. Adverse reactions in pediatric patients were similar to those reported in adults. No case of NSF associated with ProHance or any other GBCA has been identified in pediatric patients ages 6 years and younger.

Please see full Prescribing Information and Patient Medication Guide for additional important safety information for/regarding ProHance (Gadoteridol) Injection, 279.3 mg/mL at https://www.braccoimaging.com/us-en/products/magnetic-resonance-imaging/prohance

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/Safety/MedWatch or call 1-800-FDA-1088.

ProHance is manufactured for Bracco Diagnostics Inc. by BIPSO GmbH – 78224 Singen (Germany).

ProHance is a registered trademark of Bracco Diagnostics Inc.

ProHance Multipack is a trademark of Bracco Diagnostics Inc.

All other trademarks and registered trademarks are the property of their respective owners.

Bracco Diagnostics Inc.
259 Prospect Plains Road, Building H Monroe Township, NJ 08831 USA Phone: 609-514-2200
Toll Free: 1-877-272-2269 (U.S. only) Fax: 609-514-2446

© 2021 Bracco Diagnostics Inc. All Rights Reserved.